RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Subscribe To Our Newsletter & Stay Updated
